Markers for Predicting Response to Hypomethylating Agents in MDS and AML Patients / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1769-1773, 2015.
Article
en Zh
| WPRIM
| ID: wpr-272524
Biblioteca responsable:
WPRO
ABSTRACT
In many countries the hypomethylating agents (HMAs) are the major compounds to treat patients suffering from myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with low bone marrow blast counts. The elderly AML patients with poor performance status and comorbidity also benefit from HMAs. Patients who resist to HMA have a poorer outcome as compared to sensitive patients. Therefore, the reliable markers for predicting response to HMAs are urgeatly needed in clinic. In this review, the biomarkers for predicting response of patients with MDS or AML to HMAs are summarized.
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Médula Ósea
/
Síndromes Mielodisplásicos
/
Leucemia Mieloide Aguda
/
Biomarcadores de Tumor
/
Metilación
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Año:
2015
Tipo del documento:
Article